Long-Term Effects of a Long-Acting β2-Adrenoceptor Agonist, Salmeterol, on Airway Hyperresponsiveness in Patients with Mild Asthma

1992 ◽  
Vol 327 (17) ◽  
pp. 1198-1203 ◽  
Author(s):  
David Cheung ◽  
Mieke C. Timmers ◽  
Aeilko H. Zwinderman ◽  
Elisabeth H. Bel ◽  
Joop H. Dijkman ◽  
...  
Keyword(s):  
Airway Hyperresponsiveness ◽  
Mild Asthma ◽  
Long Term Effects ◽  
Adrenoceptor Agonist ◽  
Long Acting

Long-Term Effects of a Long-acting ??2-Adrenoceptor Agonist, Salmeterol, on Airways Hyperresponsiveness in Patients with Mild Asthma

1993 ◽  
Vol 37 (5) ◽  
pp. 304
Author(s):  
D. CHEUNG ◽  
M. C. TIMMERS ◽  
A. H. ZWINDERMAN ◽  
E. H. BEI ◽  
J. H. DIJKMAN ◽  
...  
Keyword(s):  
Mild Asthma ◽  
Long Term Effects ◽  
Adrenoceptor Agonist ◽  
Long Acting ◽  
Airways Hyperresponsiveness

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: A double-blind study

1991 ◽  
Vol 125 (4) ◽  
pp. 385-391 ◽  
Author(s):  
J. A. Verhelst ◽  
A. L. Froud ◽  
R. Touzel ◽  
J. A. H. Wass ◽  
G. M. Besser ◽  
...  
Keyword(s):  
Dopamine Agonist ◽  
Adverse Reactions ◽  
Double Blind Study ◽  
Long Term Effects ◽  
Double Blind ◽  
Once Daily ◽  
Long Acting ◽  
To Receive ◽  
Blind Manner

Abstract. Quinagolide (CV 205-502, Sandoz), an octahydrobenzo (g) quinoline, is a new non-ergot dopamine agonist which has specific D2 receptor activity and a long half-life, making it suitable for once-daily treatment. Recent uncontrolled reports have suggested that quinagolide may be successfully used for the clinical management of hyperprolactinemia with fewer adverse reactions than bromocriptine. This study is the first to compare quinagolide in a double-blind manner with bromocriptine, given only once-daily instead of the usual multidose regimen. In the first phase we compared, in 7 hyperprolactinemic patients, the effects over 24 h of a single oral dose of 0.05 mg quinagolide with 2.5 mg bromocriptine. Compared with placebo, both bromocriptine and quinagolide showed potent PRL-inhibiting and GH-releasing effects, with comparable effects at 24 h; no significant changes were observed in TSH, LH, FSH or cortisol. Twelve hyperprolactinemic patients were then randomized to receive either once-daily bromocriptine or quinagolide in incremental doses for a period of six months. Both drugs were found to be equally effective, and no differences were seen either in adverse reactions or PRL levels during repeated diurnal sampling. We therefore conclude that quinagolide and bromocriptine are therapeutically equivalent in long-term use, and both are equally effective when given once a day. However, some patients intolerant of bromocriptine may respond better to quinagolide, and vice versa.

Introduction to the Field Practice and Application Analysis of “Century Tianwang Bio-Organic Fertilizer” in the Past 20 Years

2021 ◽  
Vol 2 (4) ◽  
Author(s):  
Hongfeng Sun ◽  
Hongwei Luan ◽  
Xiping Chen ◽  
Guoquan Jiang ◽  
Yulin Peng ◽  
...  
Keyword(s):  
Slow Release ◽  
Organic Fertilizer ◽  
Land Restoration ◽  
Long Term Effects ◽  
High Concentration ◽  
Special Effects ◽  
Growing Period ◽  
Invention Patent ◽  
Long Acting

Abstract:Ensuring food security, increasing farmers’ income and improving people’s living standards are the focus of attention of all countries in the world today. “Centrey Tianwang” biological organic fertilizer has been upgraded to multi-functional biological organic fertilizer innovation, accepted as a new invention patent. “Centrey Tianwang” multifunctional biological organic fertilizer is a long-term natural biological organic fertilizer with high concentration. It is a new kind of slow-release fertilizer, with both quick and long-term effects. It can both fully meet the nutrient requirements of the crop, and maintain water and fertilizer, improve soil and prevent disease. It can not only control agriculture pollution, improve the crop quality and promote the yield of various crops, but also have special effects on the improvement of saline-alkali land, restoration of polluted cultivated land and degradation of agricultural residues. It is a kind of slow-release, long-acting bio-organic fertilizer that does not need any other fertilizer to be used with field crops and does not need topdressing during the whole growing period of crops. “Centrey Tianwang” multi-functional bio-organic fertilizer collects the essences of various medicinal plants, natural minerals, nano organic compounds and aerospace microbial agents, through special process, refined and processed, non-toxic, harmless, without side effects.

LONG TERM EFFECTS OF A LONG-ACTING B2-ADRENORECEPTOR AGONIST, SALMETEROL, ON AIRWAY HYPERRESPONSWENESS IN PATIENTS WITH MILD ASTHMA

PEDIATRICS ◽  
1994 ◽  
Vol 94 (2) ◽  
pp. 263-263
Author(s):  
Bradley E. Chipps
Keyword(s):  
Response Curve ◽  
Fold Increase ◽  
Beta Agonist ◽  
Double Blind Study ◽  
Long Term Effects ◽  
Double Blind ◽  
Study Population ◽  
Long Acting ◽  
Β2 Agonist

Purpose of the Study. To investigate long term effects of long-acting β2 agonist (salmeterol) on bronchodilation and bronchoconstriction caused by methacholine (MCH). Study Population. Twenty-four adult asthmatics (average age 25, range 19-36 yrs) who had not required any regular medication for 6 months. Methods. Parallel double blind study where either salmeterol 50 µg twice daily or placebo was administered during an 8-week trial. A complete dose response curve for MCH was recorded on days 0, 28, 56, and 2 and 4 days after the study ended. The PC20 (concentration required for 20% drop in FEV1) was recorded. Albuterol in an aggregate dose of 400 µg/day was allowed as rescue medication. Findings. Salmeterol caused a significant increase in FEV1 which did not change throughout the study. On the first treatment day salmeterol afforded protection against bronchoconstriction with 10-fold increase in PC20. After 4 and 8 weeks of therapy the change in PC20 returned to baseline after 4 days of washout. Reviewer's Comments. The regular use of long-acting beta agonist leads to tolerance to its protective effect against a bronchoconstrictor stimulus, although bronchodilator properties remain unchanged. Although the mechanism is unknown, this data suggests that long-term monotherapy with beta agonist may not be optimal.

scholarly journals Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly1

2001 ◽  
Vol 86 (6) ◽  
pp. 2779-2786 ◽  
Author(s):  
Annamaria Colao ◽  
Diego Ferone ◽  
Paolo Marzullo ◽  
Paolo Cappabianca ◽  
Sossio Cirillo ◽  
...  
Keyword(s):  
Somatostatin Analog ◽  
Long Term Effects ◽  
Tumor Mass ◽  
Hormone Levels ◽  
Long Acting

Ovarian Dysfunction in Fetally Irradiated Beagles

1977 ◽  
Vol 35 ◽  
pp. 658-659
Author(s):  
T. M. Seed ◽  
M. H. Sanderson ◽  
D. L. Gutzeit ◽  
T. E. Fritz ◽  
D. V. Tolle ◽  
...  
Keyword(s):  
Gamma Rays ◽  
Low Dose ◽  
Long Term Effects ◽  
Ovarian Dysfunction ◽  
Dose Rates ◽  
Highly Sensitive ◽  
Microscopic Evaluation ◽  
Ovarian Pathology ◽  
Normal Offspring

The developing mammalian fetus is thought to be highly sensitive to ionizing radiation. However, dose, dose-rate relationships are not well established, especially the long term effects of protracted, low-dose exposure. A previous report (1) has indicated that bred beagle bitches exposed to daily doses of 5 to 35 R 60Co gamma rays throughout gestation can produce viable, seemingly normal offspring. Puppies irradiated in utero are distinguishable from controls only by their smaller size, dental abnormalities, and, in adulthood, by their inability to bear young.We report here our preliminary microscopic evaluation of ovarian pathology in young pups continuously irradiated throughout gestation at daily (22 h/day) dose rates of either 0.4, 1.0, 2.5, or 5.0 R/day of gamma rays from an attenuated 60Co source. Pups from non-irradiated bitches served as controls. Experimental animals were evaluated clinically and hematologically (control + 5.0 R/day pups) at regular intervals.

Ultrastructural investigations of MDL 19,660-induced effects on the canine platelet and megakaryocyte

1990 ◽  
Vol 48 (3) ◽  
pp. 374-375
Author(s):  
D.E. Loudy ◽  
J. Sprinkle-Cavallo ◽  
J.T. Yarrington ◽  
F.Y. Thompson ◽  
J.P. Gibson
Keyword(s):  
Antidepressant Drug ◽  
Beagle Dogs ◽  
Long Term Effects ◽  
Short Term ◽  
Platelet Counts ◽  
Toxicological Studies ◽  
Induced Aggregation ◽  
Internal Architecture

Previous short term toxicological studies of one to two weeks duration have demonstrated that MDL 19,660 (5-(4-chlorophenyl)-2,4-dihydro-2,4-dimethyl-3Hl, 2,4-triazole-3-thione), an antidepressant drug, causes a dose-related thrombocytopenia in dogs. Platelet counts started to decline after two days of dosing with 30 mg/kg/day and continued to decrease to their lowest levels by 5-7 days. The loss in platelets was primarily of the small discoid subpopulation. In vitro studies have also indicated that MDL 19,660: does not spontaneously aggregate canine platelets and has moderate antiaggregating properties by inhibiting ADP-induced aggregation. The objectives of the present investigation of MDL 19,660 were to evaluate ultrastructurally long term effects on platelet internal architecture and changes in subpopulations of platelets and megakaryocytes.Nine male and nine female beagle dogs were divided equally into three groups and were administered orally 0, 15, or 30 mg/kg/day of MDL 19,660 for three months. Compared to a control platelet range of 353,000- 452,000/μl, a doserelated thrombocytopenia reached a maximum severity of an average of 135,000/μl for the 15 mg/kg/day dogs after two weeks and 81,000/μl for the 30 mg/kg/day dogs after one week.

Sign in / Sign up

Export Citation Format

Share Document